A5049887668- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Testicular diseases and treatments
- Meningioma and schwannoma management
- Cancer, Hypoxia, and Metabolism
- Neurofibromatosis and Schwannoma Cases
- EFL/ESL Teaching and Learning
- Vascular Malformations Diagnosis and Treatment
- Brain Metastases and Treatment
- Ubiquitin and proteasome pathways
- Renal and related cancers
- Drug Transport and Resistance Mechanisms
- Cancer Research and Treatments
- Lexicography and Language Studies
- Cardiac tumors and thrombi
- University Challenges and Reforms
- Mathematics, Computing, and Information Processing
- Venous Thromboembolism Diagnosis and Management
- COVID-19 diagnosis using AI
- Vasculitis and related conditions
- Political theory and Gramsci
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Hearing, Cochlea, Tinnitus, Genetics
- Blood Coagulation and Thrombosis Mechanisms
Cincinnati Children's Hospital Medical Center
2021-2024
Cure Starts Now Foundation
2024
University of Cincinnati
2023
St. Jude Children's Research Hospital
2020-2021
Nationwide Children's Hospital
2017-2021
The Ohio State University
2018-2021
Background: Clinical trials of anti-Aβ monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal (CSF) Aβ42/40.However, these measure deposits indirectly incompletely.In contrast, postmortem neuropathologic assessments allow direct investigation treatment effects on brain and many other pathologic features.Methods: From a clinical trial dominantly inherited AD, we measured...
Abstract Background Diffuse intrinsic pontine gliomas (DIPG/DMG) are devastating pediatric brain tumors with extraordinarily limited treatment options and uniformly fatal prognosis. Histone H3K27M mutation is a common recurrent alteration in DIPG disrupts epigenetic regulation. We hypothesize that genome-wide H3K27M-induced dysregulation makes vulnerable to targeting. Methods performed screen of compounds targeting enzymes identify potential inhibitors for the growth patient-derived cells....
Abstract BACKGROUND IDH-mutant gliomas comprise <10% of HGG in children. RRD-HGG 5-10% childhood HGG, demonstrate high mutation burden (TMB) and respond to immune-checkpoint inhibition (ICI). The impact RRD with gliomas, effective therapeutic options for these patients are not well-established. METHODS Clinical multi-omic analyses were performed on IDHmut-RRD-HGG registered the IRRDC glioma taskforce. Tumor development genomic data studied from a novel immunocompetent mouse model....
Abstract Background Central nervous system (CNS) germinomas are treatment‐sensitive tumors with excellent survival outcomes. Current treatment strategies combine chemotherapy radiotherapy (RT) in order to reduce the field and dose of RT. Germinomas originating basal ganglia/thalamus (BGTGs) have proven challenging treat given their rarity poorly defined imaging characteristics. Craniospinal (CSI), whole brain (WBI), ventricle (WVI), focal RT all been utilized; however, best strategy remains...
Abstract Pediatric low-grade gliomas (PLGG) have excellent outcomes overall but are a major clinical challenge when disseminated. Diffuse leptomeningeal glioneuronal tumor (DLGNT) is recognised entity both clinically and pathologically, however many disseminated LGG (DLGG) fall outside this diagnosis. To better understand the molecular features of DLGG as well risk factors for dissemination, we assembled an international consortium 30 sites, contributing over 200 patients with annotation,...
Abstract BACKGROUND Relapsed central nervous system germinomas are rare with no universal agreement regarding management. We explored the prognostic factors that may impact treatment of patients relapsed CNS germinoma. METHODS collected data on relapsed/progressive from nine large international sites. Data was summarized using descriptive statistics. Overall survival (OS) evaluated Kaplan-Meier and Fischer’s exact test to estimate odds ratios (OR) 95% confidence intervals (CI). RESULTS...
Abstract BACKGROUND Patients with relapsed/refractory central nervous system (CNS) non-germinomatous germ cell tumors (NGGCTs) have poor prognosis. We explored prognostic factors to guide the management of these patients. METHODS performed a multinational retrospective study CNS NGGCTs. Data were summarized using standard descriptive statistics. Overall survival (OS) was evaluated Kaplan-Meier and Fisher’s exact test estimate odds ratios (OR) 95% confidence intervals (CI). RESULTS identified...
Abstract BACKGROUND Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors; germinoma accounts for two-thirds of cases. While neoadjuvant chemotherapy followed by response-based reduced radiotherapy dose and field is the established approach managing localized CNS germinomas, controversy persists regarding treatment primary metastatic disease. Additionally, limited research exists on utilization in germinoma. METHODS A retrospective multi-institutional analysis was...
Abstract BACKGROUND AND AIMS IDH-mutant gliomas comprise <10% of HGG in children. RRD-HGG 5-10% childhood HGG, demonstrate high mutation burden (TMB) and respond to immune-checkpoint inhibition (ICI). The impact RRD within gliomas, effective therapeutic options for these patients are not well-established. METHODS Clinical multi-omic analyses were performed on IDH mut -RRD-HGG registered the IRRDC Toronto glioma taskforce. Tumor development genomic data studied from a novel...
Abstract Background Central nervous system (CNS) tumors are the second most common malignancy of childhood, and published data on venous thromboembolism (VTE) rate risk factors for these patients outdated or incomplete. Here, we determine cumulative incidence VTE in this population. Procedure diagnosis associated clinical were abstracted analyzed two cohorts children (0‐21 years) diagnosed with CNS between January 1, 2010 to September 30, 2018. The first study was a retrospective single...
Neurofibromatosis type 1 (NF1) is a common autosomal dominant condition caused by mutation in the NF1 tumor-suppressor gene which encodes neurofibrin, regulator of cell proliferation through RAS/MAPK pathway. patients frequently develop central nervous system low-grade gliomas (LGGs), but are also at increased risk for developing malignant tumors such as neuroblastoma combined associated with worse prognosis. The association between and has been well established, though rarely reported, its...
Gliosarcoma is rare among pediatric patients and individuals with Neurofibromatosis Type 1 (NF1). Here we compare 2 gliosarcoma patients, one of whom has NF1. We performed whole-exome sequencing, methylation, copy number analysis on tumor blood for both patients. Whole-exome sequencing showed higher mutational burden in the patient without Copy differences chromosomal losses/gains between tumors. Neither O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. The NF1 survived...
Abstract BACKGROUND Relapsed central nervous system (CNS) germinomas are rare with no universal agreement regarding management. We explore prognostic factors that may impact the treatment of patients relapsed CNS germinoma. METHODS An international multi-institutional retrospective study relapsed/progressive was conducted. Data summarized using descriptive statistics. Overall survival (OS) evaluated Kaplan-Meier and Fischer’s exact test to estimate odds ratios (OR) 95% confidence intervals...
Abstract PURPOSE Patients with relapsed/refractory central nervous system (CNS) non-germinomatous germ cell tumors (NGGCTs) have poor outcomes. There is no universal agreement on managing these patients secondary to the rarity of disease and lack prospective trials. We aim explore prognostic factors that may help guide management CNS NGGCTs. METHODS performed a multinational retrospective study summarized all data using standard descriptive statistics. Overall survival (OS) was evaluated...
Abstract Brain tumors are the second most common pediatric malignancy after leukemia. High grade gliomas have a significantly high morbidity and mortality in children, with 5-year survival rate under 20%. This study aims to identify important biological mechanisms proteins as prognostic biomarkers novel therapeutic targets. We hypothesize that higher diffuse can be effectively targeted by knocking down expression of proliferation associated protein 2G4 (PA2G4) binds MYCN prevents its...
We present the case of a 9 year old boy who was diagnosed at age four with midbrain mass projecting into 3rd. The tumor had an expanding cystic portion which required surgical management and pathology WHO Grade II glioma (Ki-67 3-8%). Parents chose to pursue holistic alternative therapies, as opposed chemotherapy. stable for almost 2 years before imaging showed progression in solid component tumor. again continue homeopathic treatment scans remained more patient developed worsening symptoms...
Gliosarcoma is a WHO grade IV histologic variant of glioblastoma that occurs very rarely among pediatric patients, even more so amongst Neurofibromatosis Type 1 (NF1) individuals. Patients with NF1-associated high-grade gliomas (HGGs) reportedly have better clinical outcomes than others despite their germline tumor-suppressor mutation. Since molecular data to explain this are lacking, we compared tumor exomes from two gliosarcoma one NF1 (P1) and without (P2). Two patients (ages 12 11...